125 results about "Cutaneous condition" patented technology

Methods for the use of prodrugs of itaconic acid and 1- and 4-methyl itaconic acid for inducing hair growth and treating an inflammatory, or immune activation (adaptive or innate), skin condition or other condition associated with hair loss are disclosed.

The present disclosure provides compounds and pharmaceutically acceptable salts thereof for inhibiting CYP26B1. Aspects of the present disclosure also include methods of using the compounds to treat diseases or disorders, including, but not limited to, skin disorders, cancer, neurological disorders, heterotopic ossification (HO), fibrodysplasia ossificans progressiva (FOP), multiple osteochondromas, and diseases or disorders of the eye, including meibomian gland dysfunction and dry eye disease.

Disclosed herein are topical nitric oxide (NO) formulations containing a surfactant and methods that deliver NO to treat skin wounds, burns, infections, site of inflammations, or other skin conditions requiring treatment, as well as to eradicate and degrade biofilms on the skin surface. The NO formulations can be modified to prolong the time of NO exposure by modulating the surfactant concentration.

The present disclosure is directed towards skin care compositions, skin care products, and methods for providing at least one skin care benefit in a subject in need thereof. More specifically, the present disclosure is directed towards methods and compositions comprising a Bacillus subtilis fermentate, Bacillus subtilis fermentate extract, or fraction thereof, for reducing dandruff, reducing a scalp or skin disorder, skin barrier strengthening, improving skin barrier function, skin moisturization, and any one combination thereof.

The invention provides a skin disease auxiliary evaluation system and device, a storage medium and a program product, and relates to the technical field of edge computation.The skin disease auxiliary evaluation system is deployed on a terminal device and comprises a feature extraction module, a feature extraction module and an evaluation module, obtaining semantic feature information corresponding to a disease description text in the skin disease information and image feature information corresponding to an affected part image in the skin disease information; the feature fusion module is used for associating the semantic feature information with the image feature information based on a cross attention mechanism to generate first multi-mode fusion feature information of the skin disease to be evaluated; and the large language model evaluation module is used for generating an evaluation result corresponding to the to-be-evaluated skin disease through a first large language model based on the first multi-mode fusion feature information.

Provided herein are systems and methods for identifying a disease or disorder of a patient, identifying if a patient is likely to respond to a treatment for the disease or disorder, and / or predicting the clinical outcome of the disease or disorder of a patient. Systems and methods described herein may be directed to patients with different chronic conditions, inflammatory conditions, and / or autoimmune conditions. Systems and methods described herein may be directed to patients with a dermatological condition.

Disclosed are effective, non-irritating, skincare formulations containing an alpha hydroxy acid and urea or a urea derivative for topical application to the skin. The disclosed topical formulations provide enhanced penetration of the active ingredients to the skin for the treatment of amenable skin conditions, such as very dry skin and keratosis pilaris, as well as for improvement of aesthetic skin properties. Also provided are methods for therapeutic treatment of dermatological conditions by topically applying a formulation comprising (% w / w) at least 10% alpha hydroxy acid and at least 10% urea. The formulations may be cream emulsions, spray-ons, among other delivery systems.

The present invention relates to an antimicrobial and healing formulation for skin, designed to effectively target and treat skin conditions such as acne caused by Cutibacterium acnes, cold sore lesions due to the herpes simplex virus, and superficial wounds. This unique formulation combines antimicrobial agents, plant extracts and essential oils in specific proportions in order to exert a synergistic action, enhancing their individual efficacy in the treatment of skin conditions and promoting skin healing. The innovative formulation composed of niaouli (Melaleuca viridiflora) essential oil and tea tree (Melaleuca alternifolia) essential oil, chlorhexidine digluconate, Hamamelis virginiana extract, panthenol, glycerol, and propylene glycol. Each ingredient has been selected for its proven pharmacological properties and its synergistic potential. The formulation works in concert to reduce microbial load, alleviate inflammation, and accelerate skin healing, while providing a gentle and effective application.

A topical application of nitric oxide may be provided by two separate containers, each containing an active component media to produce nitric oxide when combined. For example, a nitrite component media may be contained in one dispenser and an acidified component media may be contained in another dispenser. Each dispenser may dispense the respective component media as a foam or a solution. They can be combined to initiate the production of nitric oxide and the mixture of resultant foam is applied topically to treat various skin disorders or wounds.

The disclosure relates to compounds of the disclosure and pharmaceutically acceptable salts thereof to their use in medicine; to compositions containing them; to processes for their preparation; and to intermediates used in such processes. The compounds of the disclosure may be useful in the treatment, prevention, suppression and amelioration of disease(s) such as atopic dermatitis, eosinophilic gastritis, atopic keratoconjunctivitis, allergy, alopecia, Alzheimer's disease, asthma, atherosclerosis, Bechet's disease, bullous pemphigoid, cancer, chronic obstructive pulmonary disease, chronic pruritis, chronic urticaria, Crohn's disease (CD), dermatitis, diabetic kidney disease, eosinophilic esophagitis, fungal keratitis, gout, idiopathic pulmonary fibrosis (IPF), keloids, non-alcoholic steatohepatitis (NASH), primary biliary cirrhosis, prurigo nodularis, psoriasis, psoriatic arthritis, rhinosinusitis, scleroderma, systemic lupus erythematosus (SLE), systemic sclerosis, ulcerative colitis (UC), vitiligo, or hidradenitis suppurativa. The compounds of the disclosure may be useful in the treatment, prevention, suppression and amelioration of a dermatological condition or a respiratory condition.

The invention provides a light emitting adjustment method and an intense pulsed light therapeutic apparatus. The emergent light adjusting method comprises the following steps: acquiring a treatment optical filter category corresponding to a skin disease and preset light energy; the two-dimensional displacement increment of the instrument sliding on the skin surface is collected in real time, and displacement accumulation is conducted on the two-dimensional displacement increment to obtain accumulated displacement; if the accumulated displacement reaches a triggering condition, resetting the accumulated displacement and triggering output as light emitting real-time frequency; wherein the triggering condition is a product of a preset light spot width size and a height coefficient; and collecting light energy under the light emitting real-time frequency, fitting the light energy with preset light energy, calculating a calibration coefficient, and adjusting the light energy according to the calibration coefficient, so that the instrument works according to the adjusted light energy and the light emitting real-time frequency by adopting the treatment optical filter category corresponding to the skin disease. The light emitting frequency of the handle is controlled by recognizing the sliding parameters during sliding treatment, it is guaranteed that the treatment area is evenly and completely covered, and the curative effect is guaranteed.

A method for mapping one or more cutaneous conditions of a cutaneous surface may include: identifying a body map; identifying one or more body regions corresponding to the body map; identifying at least one representation corresponding to the one or more body regions; identifying one or more icons corresponding to the at least one representation; and defining the one or more icons on the at least one representation.

Provided herein are compositions and their use for the treatment of human skin, particularly facial skin, to alleviate the symptoms of cosmetic or dermatologic skin conditions. The compositions include black willow bark extract, cat's claw extract, and dragon's blood extract. The compositions ameliorate skin conditions including acne, rosacea, blemish, dermatitis, eczema, or the like.

A method of maintaining and / or improving barrier function of the skin of a human subject is disclosed herein. An embodiment of the instant method includes orally administering to a subject in need of maintenance and / or improvement of skin barrier function an effective amount of histidine and / or a derivative thereof. In some embodiments, the method may be used on a subject requiring the treatment and / or prevention of a skin disorder or condition. The barrier skin function may be assessed by measuring transepidermal water loss and administering the histidine and / or the derivative thereof in a composition comprising from about 0.5 g to about 7 g total amount of the histidine and / or derivative thereof per single dose.

The present invention relates to a patch containing an improved release liner for the treatment of various skin conditions.

The present application relates to a peptide-ionic liquid conjugate for the prevention and / or treatment of skin conditions. The peptide-ionic liquid conjugate comprises a pharmaceutical cosmetic peptide containing up to 10 amino acids and at least one ionic liquid containing a C1 to C18 saturated or unsaturated hydrocarbon chain substituent. The peptide-ionic liquid conjugates disclosed herein are useful for combating skin conditions, such as melanoma, non-melanoma skin cancer, diabetic foot ulcer, lower limb vein ulcer, stress ulcer, acne, candidiasis, cellulitis, dermatophytosis, erysipelas, folliculitis, impetigo, psoriasis, rosacea or eczema (atopic dermatitis), and the like. As they exhibit potent activity, bactericidal effect, anti-inflammatory and immunomodulatory effect and collagen production inducing effect on antibiotic sensitive strains or gram-positive and gram-negative multi-drug resistant clinical isolates. The present application further discloses topical compositions comprising the peptide-ionic liquid conjugates and uses thereof.

The present invention provides a solvent-free, non-GMO oleoresin obtained from Blakeslea trispora, comprising phytoene at a concentration of 10-40% (w / w). In addition, the invention is directed to compositions and to topical and oral dosage forms containing said oleoresin. The use of said compositions and dosage forms in the treatment and prevention of various skin conditions and for improving skin quality is also disclosed and claimed.

A formulation for topical administration of timolol maleate is disclosed. The formuation, when administered at a daily dose from about 0.4 to about 15 mg / cm2 / day, provides a steady state mean timolol blood Cmax,ss below 3ng / ml in a subject in need thereof, wherein at steady state the ratio of Cmax,ss / Cmin,ss is less than 2. Also disclosed herein is a method of treating skin conditions such as infantile hemangiomas and chronic venous leg ulcer.

The present invention provides a formulation for application to the skin and pharmaceutical uses of the formulations of the invention. The present invention also provides methods of delivering a medicament to a subject and kits for treating a subject having a skin condition.

The present invention relates to a composition, in particular a cosmetic composition, comprising, in a physiologically acceptable medium, at least one endolysin derived from Staphylococcus aureus bacteriophage and at least one oil other than liquid paraffin. The invention also relates to the use of such a composition for the prevention and / or treatment of skin conditions associated with colonization of Staphylococcus aureus in a subject in need thereof, and in particular for the prevention and / or treatment of acne and / or eczema in a subject, and to a non-therapeutic cosmetic method for caring for keratin materials, in particular skin, it comprises at least one step of topically applying such a composition to the keratin material.

The present invention provides a medical implant, comprising (a) a matrix layer comprising chitosan; and (b) a reinforcement structure comprising polymer filaments or polymer fibers, whereby the reinforcement structure is incorporated into the matrix layer. The invention further relates to the medical implant for use in the treatment of ophthalmological diseases or skin disorders. The invention finally relates to a method for producing the medical implant of the invention.

The present disclosure relates to cyclic oligopeptides that bind to interleukin-13 (IL-13) which are useful therapeutically in methods of treating or preventing IL-13-associated skin disorders or conditions. The present disclosure also provides methods to treat or prevent IL-13-associated skin disorders or conditions with the IL-13-binding cyclic oligopeptides. The present disclosure further provides methods to produce the IL-13-binding cyclic oligopeptides.

The present disclosure describes methods of treating a skin disorder in a subject in need thereof and methods of locally suppressing an immune response in a tissue of a subject in need thereof. The methods can include contacting a microneedle array comprising a plurality of microneedles with a skin surface of the subject, wherein the plurality of microneedles comprises: i) a degradable hyaluronic acid polymer comprising a disulfide bond, and ii) a therapeutic agent; and applying pressure on the microneedle array such that the plurality of microneedles penetrates the skin surface, thereby releasing the therapeutic agent beneath the skin surface while simultaneously capturing ISF for successive analysis.

This method involves treating a patient's skin condition or disease by topically applying a pharmaceutical composition containing roflumilast. Treatment methods include once-daily application of the roflumilast composition for a period of time, followed by twice-weekly application of the roflumilast composition as a maintenance dosing regimen.

Modulated light therapy devices for treatment of dermatological disorders of the scalp are provided. An exemplary device includes a flexible printed circuit board (FPCB) supporting at least one light emitting device having an emitter height. The FPCB includes multiple interconnected panels and bending regions defined in and between at least some of the interconnected panels as to allow the FPCB to be configured in a concave shape to cover at least a portion of a cranial vertex of the patient. At least one light-transmissive layer proximate to the FPCB is configured to transmit (e.g., incoherent) light emissions generated by at least one light emitting device. At least one standoff is configured to be arranged between the FPCB and the scalp of the patient, wherein the at least one standoff includes a standoff height that exceeds the emitter height.

Provided herein are polyphenol-enriched lettuce powders comprising particles of a polyphenol-enriched lettuce or extract, wherein the polyphenol-enriched lettuce comprises from 40-280 mg / g of polyphenols. The polyphenols include any combination of a chlorogenic acid, a neochlorogenic acid, a chicoric acid, a quercetin, a quercetin derivative, and an anthocyanin. The disclosure also provides compositions and methods of using the polyphenol-enriched lettuce powders to promote wound healing and treat inflammation and skin disorders.

The disclosure relates to compounds of the disclosure and pharmaceutically acceptable salts thereof to their use in medicine; to compositions containing them; to processes for their preparation; and to intermediates used in such processes. The compounds of the disclosure may be useful in the treatment, prevention, suppression and amelioration of disease(s) such as atopic dermatitis, eosinophilic gastritis, atopic keratoconjunctivitis, allergy, alopecia, Alzheimer's disease, asthma, atherosclerosis, Bechet's disease, bullous pemphigoid, cancer, chronic obstructive pulmonary disease, chronic pruritis, chronic urticaria, Crohn's disease (CD), dermatitis, diabetic kidney disease, eosinophilic esophagitis, fungal keratitis, gout, idiopathic pulmonary fibrosis (IPF), keloids, non-alcoholic steatohepatitis (NASH), primary biliary cirrhosis, prurigo nodularis, psoriasis, psoriatic arthritis, rhinosinusitis, scleroderma, systemic lupus erythematosus (SLE), systemic sclerosis, ulcerative colitis (UC), vitiligo, or hidradenitis suppurativa. The compounds of the disclosure may be useful in the treatment, prevention, suppression and amelioration of a dermatological condition or a respiratory condition.

A method for mapping one or more cutaneous conditions of a cutaneous surface may include: identifying a body map; identifying one or more body regions corresponding to the body map; identifying at least one representation corresponding to the one or more body regions; identifying one or more icons corresponding to the at least one representation;and defining the one or more icons on the at least one representation.

The present disclosure relates to a method of treating a neutrophilic skin condition in a subject. The methods comprise subcutaneous administration of a fixed dose of an antibody that inhibits granulocyte colony stimulating factor (G-CSF) signaling to the subject.